On December 11, 2023, Aditxt entered into a merger agreement with Evofem, which was amended on July 12, 2024. The third amendment to the Form 8-K, filed on November 21, 2024, includes Evofem's financial statements for the nine months ended September 30, 2024. The merger will result in Evofem becoming a wholly owned subsidiary of Aditxt. The amendment provides historical and pro forma financial data, showing Evofem's net loss of $2.4 million for the nine months ended September 30, 2024. The pro forma financials are for informational purposes and do not predict future results. Aditxt's CEO, Amro Albanna, signed the report, emphasizing the strategic importance of the merger. The amendment does not update other items from the original report.

On December 11, 2023, Aditxt entered into a merger agreement with Evofem, which was amended on July 12, 2024. The third amendment to the Form 8-K, filed on November 21, 2024, includes Evofem's financial statements for the nine months ended September 30, 2024. The merger will result in Evofem becoming a wholly owned subsidiary of Aditxt. The amendment provides historical and pro forma financial data, showing Evofem's net loss of $2.4 million for the nine months ended September 30, 2024. The pro forma financials are for informational purposes and do not predict future results. Aditxt's CEO, Amro Albanna, signed the report, emphasizing the strategic importance of the merger. The amendment does not update other items from the original report.